Servier and Taiho Oncology to Present P-III Trial (SUNLIGHT) Results of Lonsurf (trifluridine/tipiracil) for Metastatic Colorectal Cancer at 2023 ASCO GI
- The P-III trial (SUNLIGHT) evaluating Lonsurf + bevacizumab vs trifluridine/tipiracil alone in a ratio (1:1) in 492 patients with refractory mCRC, following 2 CT regimens
- The trial met its 1EPs i.e., the therapy showed a clinical improvement in OS (10.8 vs 7.5mos.) with a 39% reduction in the risk of death & the 2EPs also showed an improvement in PFS (5.6 vs 2.4mos.), patients experienced sev. AEs (72.4% vs 69.5%). The combination therapy may be effective & well-tolerated
- The data will be submitted to regulatory authorities by both companies to quickly deliver the novel combination to patients. Lonsurf is an oral nucleoside antitumor agent which was discovered & developed by Taiho Pharmaceutical
Ref: PRNewswire | Image: Servier
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.